EGFR and non-small cell lung carcinoma: EGFR monoclonal antibodies (cetuximab and panitumumab) that target the EGFR are approved for treatment of colorectal, head, and neck cancers, whereas its development in NSCLC has not taken its place in routine clinical practice, because of limited clinical benefit despite statistically significant Phase III trials [8].